Zymeworks Inc. has finished its purchase of Theravance Biopharma. The deal, closed on September 23, 2026, puts Zymeworks in a stronger spot among biotech firms focused on revenue. With this move, Zymeworks now controls more assets and brings in more commercial and royalty income.
Theravance Biopharma shareholders approved the merger at an extraordinary general meeting on September 18, 2026, clearing the final corporate approval step before closing.
An official SEC filing shows the deal was worth about $929 million. Theravance shareholders will get $17.00 in cash for each share. The agreement also gives them a contingent value right. This means they will get 80% of any future net proceeds from licensing, selling, or monetizing ampreloxetine over the next ten years, as covered in recent market reports.
Zymeworks plans to answer investor questions and public interest with a conference call at 8:30 am ET on September 28. Details and a webcast link are on the company’s investor relations site. A replay will be posted within 24 hours for those who miss the live call.
The acquisition was described in SEC-linked material event filings as a move in which Theravance Biopharma became a wholly owned subsidiary of Zymeworks after Zymeworks Merger Sub 1 merged into Theravance. This structure was confirmed in regulatory disclosures on the day of closing.
Still, Zymeworks is careful not to overpromise. The company’s forward-looking statements say that any benefits from the Theravance deal, future milestone payments, and sales of drugs like YUPELRI® and TRELEGY® all depend on many unknowns. There are regulatory hurdles, clinical trial risks, and the ups and downs of the commercial market. Zymeworks tells investors not to count too much on projections, making clear that all forecasts are based on current assumptions and may not play out as planned.
Now that Theravance Biopharma is under its roof, Zymeworks is betting on a mix of new drug development and a stronger, more varied revenue base. This is not just a pipeline gamble. It is a move toward financial stability and more control in a field known for big swings. The real question is whether Zymeworks can turn this bigger portfolio into steady growth and value for shareholders, or if the risks of biotech deals will slow things down. For now, Zymeworks has made its play, and the industry will be watching to see if this strategy brings the lasting returns that many biotech firms want but few actually get.
